News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bayer Yakuhin Ltd. Has Filed Fosrenol(R) For The Treatment Of Hyperphosphatemia In Japan



12/20/2006 12:24:11 PM

Osaka, Japan, Dec 20, 2006 - (JCN Newswire) - Bayer Yakuhin Ltd. has submitted a marketing application for Fosrenol(R) (lanthanum carbonate) for the treatment of hyperphosphatemia in end stage renal disease (ESRD) patients in Japan. Bayer Yakuhin received an exclusive license from Shire International Licensing BV in December, 2003 to develop and sell Fosrenol(R) in Japan and completed Phase II and Phase III clinical trials in Japan.

Read at JCN Newswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES